Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Phase 2
Completed
- Conditions
- Primary Peritoneal CarcinomaOvarian CancerUterine CancerCervical CancerFallopian Tube CancerBreast CancerEndometrial Cancer
- Interventions
- Biological: Vigil
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Mary Crowley Medical Research Center
- Target Recruit Count
- 13
- Registration Number
- NCT02725489
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
Blood for Immune Response to Provenge® in HRPC
Withdrawn
- Conditions
- Prostate Cancer
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Mary Crowley Medical Research Center
- Registration Number
- NCT01274572
Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer
Phase 1
Terminated
- Conditions
- Carcinoma, Advanced Metastatic
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Mary Crowley Medical Research Center
- Target Recruit Count
- 46
- Registration Number
- NCT00684294
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
News
No news found